WeCare Probiotics Makes a Striking Debut on Day One of CPHI China 2025 and HNC 2025

SHANGHAI, CHINA – June 25, 2025 – WeCare Probiotics is thrilled to announce a highly successful start to CPHI China 2025 and HNC 2025, marking a significant milestone on the exhibition's opening day. The company's commitment to "Clinical Evidence-Based Science" has resonated strongly with attendees, drawing considerable interest and fostering numerous new connections.

From the moment the doors opened this morning, WeCare Probiotics' booth was a hub of activity. The team engaged with so many clients and prospective partners, demonstrating the burgeoning demand for innovative and scientifically validated probiotic solutions. This intense engagement led to countless detailed inquiries, covering a wide spectrum of applications and collaboration opportunities.

Key discussions revolved around WeCare's flagship, clinically-backed strains:

• B. animalis subsp. lactis BLa80: Highlighted for its 15+ clinical studies and GRAS affirmation.

• Weizmannia (Bacillus) coagulans BC99: Noted for its 10+ clinical trials and impressive global export success, with 90% going to the United States.

• L. rhamnosus LRa05: Showcased for its extensive research, including 14+ clinical studies and 25 patents.

• Akkermansia muciniphila Akk11: Generating significant buzz with its two sales specifications and substantial annual production capacity, validated by clinical trials and GRAS status.

Beyond initial discussions, WeCare Probiotics is proud to report the successful establishment of several significant agreements and strong consensus with new partners on Day One. These early successes underscore the effectiveness of WeCare's approach and the market's readiness for high-quality, research-driven probiotic ingredients. The dedicated team at the booth tirelessly conducted in-depth presentations, provided comprehensive product information, and engaged in valuable networking to solidify these foundational relationships.

About WeCare Probiotics: WeCare Probiotics is a leading innovator in the field of probiotic ingredients, committed to developing and supplying clinically evidence-based strains for a wide range of applications. With a focus on scientific research, patented technologies, and stringent quality control, WeCare Probiotics aims to empower health and wellness globally through superior probiotic solutions.